Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 10;8(3):1535293. doi: 10.1080/2162402X.2018.1535293

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 4. — Gene expression of TAAs in HNSCC/mucosa and serological detection of TAA-specific antibodies in HNSCC patients and healthy donors.

(A) Gene expression data of 23 different TAAs was obtained from TCGA HNSCC samples and is summarized in a heatmap. Results from non-cancerous mucosa are displayed on the left (n = 44), followed by HPV⁻ (n = 72) and HPV⁺ (n = 32) HNSCC color-coded as indicated in the legend on the right. (B) Serological antibodies against 23 TAAs were measured by Luminex bead assay. Respective MFI levels are shown in a heatmap (color code on right side). Samples obtained from healthy donors (n = 15; left) were compared to HNSCC patient derived serum samples (HPV⁻, n = 27; middle; HPV⁺, n = 9; right). (C) TAA antibody detection is summarized in stacked graphs, comparing healthy controls (HC) with HNSCC patients on the left and stratifying data from HNSCC patients according to HPV status, disease stage (UICC) and MHC-I expression level of respective primary tumors. Positive results with TAA-specific MFI levels > 200 per patient were summed up. Antibodies against none up to a maximum of five TAAs were detected in single subjects.